PARC Antibody (NQ-C32): sc-134412

PARC Antibody (NQ-C32) is a mouse monoclonal IgG2a kappa light chain antibody that detects PARC protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-PARC antibody (NQ-C32) is available as a non-conjugated format. PARC protein, or p53 associated Parkin-like cytoplasmic protein, plays a crucial role in regulating tumor suppressor p53, which is altered in over 50% of human cancers. By acting as a cytoplasmic anchor for p53 in unstressed cells, PARC helps maintain proper localization and function of p53, ensuring effective response to cellular stress and DNA damage. Notably, PARC protein′s C-terminus contains a RING-IBR-RING domain, indicating potential ubiquitin ligase activity; however, PARC does not promote p53 degradation, highlighting a unique regulatory role. The gene encoding human PARC is located on chromosome 6p21.1, and understanding PARC function is vital for elucidating mechanisms of tumor suppression and cellular response to DNA damage.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PARC Antibody (NQ-C32) References:

1. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53.  |  Oda, K., et al. 2000. Cell. 102: 849-62. PMID: 11030628
2. Parc: a cytoplasmic anchor for p53.  |  Nikolaev, AY., et al. 2003. Cell. 112: 29-40. PMID: 12526791
3. Analysing p53 tumour suppressor functions in mice.  |  Sluss, HK. and Jones, SN. 2003. Expert Opin Ther Targets. 7: 89-99. PMID: 12556205
4. MDM2 is a central node in the p53 pathway: 12 years and counting.  |  Bond, GL., et al. 2005. Curr Cancer Drug Targets. 5: 3-8. PMID: 15720184
5. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified.  |  Mayo, LD., et al. 2005. J Biol Chem. 280: 25953-9. PMID: 15843377
6. PARC and CUL7 form atypical cullin RING ligase complexes.  |  Skaar, JR., et al. 2007. Cancer Res. 67: 2006-14. PMID: 17332328
7. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease.  |  Sin, DD., et al. 2011. Am J Respir Crit Care Med. 183: 1187-92. PMID: 21216880
8. PARC/CCL18 is Associated with Inflammation, Emphysema Severity and Application of Inhaled Corticosteroids in Hospitalized COPD Patients.  |  Duan, H., et al. 2021. Int J Chron Obstruct Pulmon Dis. 16: 1287-1297. PMID: 34007168
9. New approach methodologies to facilitate and improve the hazard assessment of non-genotoxic carcinogens-a PARC project.  |  Audebert, M., et al. 2023. Front Toxicol. 5: 1220998. PMID: 37492623
10. Innovative tools and methods for toxicity testing within PARC work package 5 on hazard assessment.  |  De Castelbajac, T., et al. 2023. Front Toxicol. 5: 1216369. PMID: 37538785
11. Two cellular proteins that bind to wild-type but not mutant p53.  |  Iwabuchi, K., et al. 1994. Proc Natl Acad Sci U S A. 91: 6098-102. PMID: 8016121
12. Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2.  |  Iwabuchi, K., et al. 1998. J Biol Chem. 273: 26061-8. PMID: 9748285

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-PARC Antibody (NQ-C32) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-PARC Antibody (NQ-C32) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

PARC Antibody (NQ-C32) Specifications

Alternate Product Name: PARC

Product Clone Name: NQ-C32

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 918-1026

Epitope Target: PARC

Epitope Species: human

Product Reactivity/Detection: PARC

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, ELISA

Vialing Information: Each vial contains 100 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for PARC Antibody (NQ-C32): N/A